This is a pilot study to determine proof in principle that vilazodone, a selective serotonin
reuptake inhibitor and 5HT1a agonist, reduces the frequency and severity of menopausal hot
flashes relative to placebo. A secondary aim is to evaluate improvement in menopause-related
quality of life.